Why Gastroenterology Became a Private Equity Target

Gastroenterology has several characteristics investors find appealing. It remains relatively fragmented, with many physician-owned groups that can be combined through a “platform and add-on” strategy. It also includes a dependable mix of office visits, procedures, ambulatory surgery centers, pathology, anesthesia, infusion therapy, clinical research, and other ancillary services.

Demand is supported by an aging population, chronic digestive diseases, and colorectal cancer screening. Because colonoscopy screening now commonly begins at age 45 for adults at average risk, the potential patient pool is substantial. Unlike a technology startup hoping that someone eventually buys its app, an established GI group already has patients, physicians, equipment, contracts, and recurring revenue.

A 2022 analysis found that 7.4% of gastroenterologists were affiliated with private equity-acquired practices in 2019, placing gastroenterology among the most heavily penetrated office-based specialties examined. More recent research reported that approximately 13.1% of gastroenterologists worked in practices owned by private equity, although estimates differ according to methodology and the definition of ownership.

How a Private Equity Gastroenterology Deal Usually Works

A private equity sponsor typically begins by investing in a sizable gastroenterology group known as the platform practice. The platform then acquires or affiliates with smaller groups in nearby or strategically important markets. This “roll-up” approach can expand geographic reach, centralize administrative operations, and increase bargaining leverage with insurers.

The Role of the Management Services Organization

Because many states restrict the corporate practice of medicine, transactions are frequently structured through a management services organization, or MSO. Physicians may continue to own or control the clinical entity, while the MSO manages nonclinical assets and services such as billing, human resources, information technology, purchasing, marketing, and real estate.

On paper, the boundary appears simple: doctors make medical decisions, and business managers handle business matters. In practice, staffing levels, scheduling templates, productivity targets, service-line investments, and compensation formulas can indirectly shape clinical care. A spreadsheet cannot perform a colonoscopy, but it can certainly decide how many colonoscopies should fit into a Tuesday.

Cash at Closing and Rollover Equity

Physician owners commonly receive an upfront payment based on a multiple of adjusted earnings. They may also reinvest part of the proceeds into the new organization, creating “rollover equity.” The hope is that the platform grows and is later sold at a higher valuation, producing a second financial return.

The physician generally becomes an employee after the transaction, often with a new compensation arrangement. Income may be reduced to create the earnings used to justify the purchase price. Restrictive covenants, productivity requirements, governance rights, retirement rules, and the treatment of younger partners vary widely. The headline valuation is therefore only the opening paragraph, not the entire novel.

Federal analysis describes private equity investments as commonly lasting approximately three to 10 years. Sponsors may use debt, charge management fees, consolidate practices through an MSO, and ultimately seek an exit through a sale, recapitalization, or transfer to another investor.

What the Evidence Says About Prices and Spending

The clearest research finding is not that private equity always damages care. It is that acquisition is frequently associated with higher prices, spending, or utilization.

Colonoscopy Prices Increased After Acquisition

A 2025 JAMA Health Forum study evaluated roughly 1.3 million colonoscopies involving more than 1.1 million commercially insured patients. Compared with independent practices, colonoscopy prices at private equity-acquired gastroenterology sites increased by 4.5%. In practices with relatively high market share, the estimated increase reached 6.7%.

Spending on colonoscopies per physician increased by 16%, while colonoscopy volume per physician rose by 12.1% and the number of unique patients rose by 11.3%. The researchers cautioned that utilization measures were already trending upward before acquisition, making it difficult to attribute every additional procedure directly to the new owner.

Professional Fees May Be a Major Lever

A separate 2025 Health Affairs analysis compared private equity-owned gastroenterology practices with independent and health system-affiliated groups. After acquisition, the total price per claim increased by an estimated $92, or 28.4%. The change was driven largely by a 78.1% increase in professional fees, while the study did not find a statistically significant change in facility fees.

Earlier research covering gastroenterology, dermatology, and ophthalmology found an 11% increase in the allowed amount per claim after private equity acquisition. Acquired practices also recorded more unique patients, more new patients, and more total encounters than matched independent practices. These changes could reflect expanded access, improved marketing, stronger referral networks, better billing capture, greater coding intensity, or some combination of the above.

What About Quality of Care?

The 2025 colonoscopy study examined six quality and safety measures, including incomplete procedures, polypectomy, cardiovascular events, bleeding, infection, perforation, and other post-procedure complications. It found no statistically significant change in those measures after private equity acquisition.

That finding deserves a careful interpretation. It does not demonstrate that private equity improved quality, but it also does not show that the acquisitions made colonoscopy measurably less safe. Some serious complications are rare, making changes difficult to detect. Claims-based measures may also miss important dimensions such as bowel-preparation quality, adenoma detection, patient communication, staff continuity, wait times, and physician burnout.

An accompanying JAMA commentary emphasized that the effect of private equity on prices and spending is currently clearer than its effect on access and clinical quality. Increased throughput might represent improved efficiency and greater availability, strategic use of market power, or both at the same time. Health care, inconveniently for headline writers, does not always provide a one-villain plot.

The Potential Benefits of Private Equity Partnerships

Private equity can provide real advantages, particularly for practices struggling to remain independent while competing with large hospital systems and insurer-owned groups.

Investment capital can fund electronic health record upgrades, cybersecurity, centralized scheduling, revenue-cycle improvements, new endoscopy centers, equipment replacement, compliance programs, data analytics, and recruitment. A larger organization may negotiate better vendor contracts and provide professional management that a small practice cannot afford on its own.

Centralized administration can also remove routine burdens from physicians. If an MSO successfully handles claims denials, credentialing, payroll, purchasing, and regulatory reporting, physicians may have more time for care. Practices may gain resources to open locations in underserved communities, hire additional clinicians, or improve access to subspecialty services.

For senior partners, a transaction can convert years of practice-building into a liquid financial asset. For some groups, private equity may also offer a way to preserve an outpatient identity rather than selling to a hospital. A well-designed partnership with physician governance, reasonable debt, long-term investment, and meaningful quality safeguards can be preferable to other consolidation options.

Professional organizations recognize that these deals require sophisticated evaluation. The American College of Gastroenterology has advised physicians to examine ownership rights, liabilities, operational control, culture, and post-sale obligations with experienced legal and financial counsel.

The Risks Physicians and Patients Should Not Ignore

Loss of Physician Autonomy

Clinical authority may be formally protected while operational decisions shift elsewhere. Physicians may have less control over staffing, schedules, technology, compensation, hiring, and expansion. A corporate board does not need to order a specific test to influence care; it can affect the environment in which thousands of testing decisions occur.

Pressure for Faster Growth

Private equity funds generally have defined investment horizons. That creates pressure to increase earnings before an exit. Growth may come from legitimate efficiency, but it may also depend on higher prices, greater procedure volume, expanded ancillaries, reduced expenses, or aggressive acquisition activity.

Debt and Exit Risk

Leveraged transactions can place debt obligations within the acquired organization. Those obligations may limit flexibility during reimbursement cuts, labor shortages, cyberattacks, or economic downturns. Rollover equity can produce a profitable “second bite,” but it is not guaranteed. Its value depends on debt, future buyers, market conditions, and the rights attached to the physician’s ownership class.

Workforce and Culture Changes

A 2024 survey of 525 physicians found that most respondents viewed private equity involvement negatively, particularly regarding physician well-being, costs, and health equity. The number of physicians in the survey who actually worked for private equity-owned entities was small, so the results should not be treated as a universal verdict. Still, the findings highlight the importance of autonomy, professional satisfaction, and retention.

Market Concentration

Individual practice acquisitions may be too small to trigger federal premerger reporting, even when a series of purchases creates a dominant regional platform. The U.S. Government Accountability Office reported that private equity investment remains a minority of physician ownership nationally but can be highly concentrated in particular specialties and markets. It found that private equity-backed groups employed more than 30% of gastroenterologists in about 11% of metropolitan areas examined.

Federal regulators have consequently increased their attention to serial acquisitions and health care consolidation. The FTC, Department of Justice, and Department of Health and Human Services have sought information about transactions that may reduce competition, raise costs, or affect quality and working conditions.

Questions Gastroenterologists Should Ask Before Signing

A physician group evaluating a private equity offer should examine much more than the purchase multiple. Important questions include:

• Who has final authority over staffing, scheduling, clinical protocols, equipment, and quality programs?
• How will physician compensation change immediately and over the next five years?
• What debt will be placed on the organization, and who is responsible for servicing it?
• What voting, information, and liquidation rights come with rollover equity?
• How are pathology, anesthesia, infusion, research, pharmacy, and ambulatory surgery center revenues treated?
• What happens to physicians who retire, resign, become disabled, or fail to meet productivity targets?
• How restrictive are noncompete, nonsolicitation, and termination provisions?
• How will new associates earn equity, and will the transaction create tension between generations?
• What happens if the platform is sold to another sponsor, insurer, distributor, or public company?
• Which patient-access, safety, experience, and quality measures will be publicly monitored?

Independent legal, tax, valuation, and operational advice is essential. The buyer’s advisers work for the buyer. The practice needs advisers who are paid to identify unpleasant details before those details become expensive surprises.

What Patients Can Ask

Patients do not need to become amateur investment bankers, but they are entitled to understand who participates in their care. Useful questions include whether the practice or endoscopy center has changed ownership, whether a procedure will generate separate facility, anesthesia, or pathology bills, and whether every participating provider is in network.

Patients can also ask whether a recommended procedure follows current screening or surveillance guidelines, whether a lower-cost site is available, and how follow-up concerns will be handled. Ownership alone does not determine whether a doctor is excellent. Transparency simply helps patients understand the financial system surrounding the clinical relationship.

What Better Oversight Could Look Like

Policy should focus on conduct and outcomes rather than assuming every private equity transaction is identical. Potential reforms include stronger ownership disclosure, reporting of smaller serial acquisitions, monitoring of regional market concentration, and clearer information about debt and management fees.

Regulators and payers could track procedure prices, coding intensity, payer mix, wait times, physician turnover, staffing, adverse events, and validated quality measures before and after acquisition. Antitrust reviews should consider the cumulative effect of add-on transactions rather than evaluating each practice purchase in isolation.

At the practice level, contracts can protect physician-led clinical governance, establish minimum staffing standards, and tie part of executive compensation to patient-centered outcomes. Capital and efficiency are not enemies of good medicine. The real question is whether financial incentives support the purpose of gastroenterology or quietly become its substitute.

Experiences From the Field: What Private Equity Can Feel Like

Note: The following experience-based examples are realistic composite scenarios informed by reported transaction structures and physician concerns. They do not describe one specific practice or claim to be the author’s personal experiences.

The Senior Partner’s Experience

Consider a senior gastroenterologist who helped build a six-physician group over 25 years. The practice has a respected name, an ownership stake in an endoscopy center, and a billing department that operates through a combination of skill, institutional memory, and one employee who apparently knows every insurance representative in the state.

A buyer offers the partners a substantial upfront payment and promises professional management. For the senior physician, the deal solves several problems at once. Retirement becomes financially secure, responsibility for recruiting shifts to a larger organization, and the practice gains access to technology it had delayed purchasing.

Two years later, the doctor may still appreciate the transaction while missing the old partnership meetings. Decisions that once required a conversation down the hallway now require approval from regional management. The financial outcome may be excellent, but ownership feels different after the owner becomes an employee.

The Early-Career Gastroenterologist’s Experience

A newly trained gastroenterologist may join after the sale and see the same deal very differently. The organization offers a competitive salary, efficient onboarding, modern facilities, and a predictable schedule. There is no requirement to borrow money for a traditional partnership buy-in, which can be appealing after years of medical training.

However, the younger physician may discover that legacy partners received transaction proceeds while new doctors receive productivity compensation without equivalent ownership opportunities. Rollover equity may be restricted to senior physicians or offered under different terms. The organization can still be a good workplace, but the traditional promisework hard, become a partner, help govern the practicemay no longer exist.

Recruitment materials should therefore explain the actual career path, not merely use the word “partnership” because it looks friendly in a brochure.

The Practice Administrator’s Experience

For an administrator, private equity can feel like replacing a collection of homemade spreadsheets with an airport control tower. Centralized purchasing, compliance, credentialing, and revenue-cycle teams may solve persistent problems. Data arrive faster, denials are tracked systematically, and nobody has to guess which endoscope lease expires next month.

The trade-off is a new reporting rhythm. Monthly dashboards, earnings targets, standardized staffing ratios, and integration deadlines can arrive quickly. Local managers may spend less time fixing old administrative problems but more time explaining why Tuesday’s procedure volume missed the forecast. Whether this feels like welcome professionalism or excessive corporate pressure depends heavily on leadership and expectations.

The Patient’s Experience

Many patients may notice nothing. The physician, office sign, and procedure room remain the same. Scheduling may become easier, online communication may improve, and the larger network may offer faster access to a subspecialist.

Other patients may encounter centralized phone systems, unfamiliar bills, or a recommendation to use an affiliated endoscopy center, pathology service, or anesthesia group. None of those arrangements is automatically inappropriate. Problems arise when financial relationships are opaque or patients are not informed about alternatives and costs.

These experiences show why the debate cannot be reduced to “private equity good” or “private equity bad.” Outcomes depend on governance, leverage, market concentration, physician leadership, transparency, and what the organization chooses to optimize. The gastroenterology groups most likely to thrive will treat the transaction as the beginning of a long clinical and cultural commitmentnot merely the happiest day on a banker’s calendar.

Conclusion

It is time to talk openly about private equity in gastroenterology because the ownership of medical practices affects more than balance sheets. It can influence prices, access, physician autonomy, staffing, investment, and the future structure of outpatient digestive care.

Private equity can supply valuable capital and management expertise. It may help groups remain independent of hospitals, improve administrative systems, and create liquidity for retiring partners. At the same time, recent evidence repeatedly associates acquisitions with higher prices and utilization without clearly demonstrated improvements in quality.

The appropriate response is neither panic nor blind enthusiasm. Physicians should negotiate with their eyes open, patients should receive meaningful transparency, and policymakers should monitor cumulative consolidation rather than waiting until a regional market has already been rolled into one very profitable burrito.

SEO Information